Kringle Pharma Commences a Phase I/II Clinical Trial in Sweden on ChronSeal®, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers
- January 28, 2009
Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO: Kunio Iwatani, "KRINGLE") is proud to announce that the clinical trial application of ChronSeal® to the Swedish authority, Medical Products Agency (MPA), dated 23 December 2008 was approved on 23 January 2009. Having its approval granted by the authority, KRINGLE will conduct a phase I/II clinical trial of ChronSeal® in Sweden.
Link to the website of the press release(28 January 2009) from Kringle Pharma, Inc. is here.
Link to the website of the press release(28 January 2009) from Kringle Pharma, Inc. is here.
